Public advisory - Rhinaris Nasal Mist: One lot recalled due to risk of microbial growth which may lead to infection
OTTAWA, ON, July 7, 2023 /CNW/ -
Summary
Product: Rhinaris Nasal Mist 30 mL (lot 230391A)
Issue: Health products - Product safety
What to do: Do not use this product. Return it to your local pharmacy for proper disposal. Consult a health care professional if you have used this product and have health concerns.
Images
Affected products
Product
DIN
Lot
Expiry date
UPC
Rhinaris Nasal Mist 30 mL
02354551
230391A
31-05-2025
5760622302
Issue
The Pendopharm Division of Pharmascience Inc. is recalling one lot of Rhinaris Nasal Mist due to the risk of microbial growth. Using a product contaminated with microbes may lead to rhinosinusitis (a sinus infection). Children, pregnant people, seniors and people with weaker immune systems may be more susceptible to infection or complications from microbial contamination.
Rhinaris Nasal Mist is an over-the-counter drug used to moisturize and lubricate dry nasal passages in adults and children at least two years of age.
The company's testing showed that the preservative in the product may not be as effective as expected, which could lead to an increased risk of growth of microbes such as molds or bacteria over time if they are introduced into the product.
Although rare, rhinosinusitis can lead to more serious complications, such as nasal abscesses (a collection of pus), cellulitis (skin infection) or meningitis (infection and inflammation of the fluid and membranes surrounding the brain and spinal cord).
While the growth of other microbes may be possible, the testing showed that the preservative may not prevent the growth of a specific type of bacteria called Pseudomonas aeruginosa if it is introduced into the product. For someone whose immune system has been weakened by other serious conditions, especially cystic fibrosis, HIV/AIDS, severe lung disease, cancer, diabetes, or burns, Pseudomonas aeruginosa can cause serious infections including pneumonia, bone infections, urinary tract infections, gastrointestinal infections, meningitis, and blood infections.
What you should do
Do not use this product. Return it to your local pharmacy for proper disposal.
Consult a health care professional if you have used this product and have health concerns.
Contact Pendopharm Division of Pharmascience Inc. by calling 1-888-550-6060 or emailing [email protected] if you have questions about this recall.
Children's HealthSM and UT Southwestern Medical Center announced a historic gift of $100 million from the Jean and Mack Pogue family in support of the $5 billion new Dallas pediatric campus, unveiled earlier this year. The gift from the Pogue...
Amgen will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS)...
Baltimore Urban Gardening with Students (BUGS), a program operated by The Crossroads School, a Living Classrooms Foundation Charter School, is excited to announce its 26th Annual Youth Farmer's Market taking place on Saturday, May 18th, from 9:00 AM...
DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") , a healthcare technology company focused on brain health using AI, is pleased to announce that it is arranging a private placement of a minimum of $400,000 and a maximum of $650,000 of units...
A new guideline has been issued to help neurologists and other clinicians determine the best antiseizure medications for people with epilepsy who may become pregnant. The guideline is published in the May 15, 2024, online issue of Neurology®, the...
The leading cause of death worldwide is chronic inflammatory diseases. When the body is inflamed and under stress for long periods of time, the body's heart rate increases, increasing the risk of fatality. A new study published in Brain, Behavior and...